Glooko and MyLife Diabetes Care announced today that they agreed to expand their partnership centered around diabetes management products. Under their agreement, Glooko serves as MyLife Diabetes Care’s primary data management platform for MyLife products. Glooko offers diabetes management platforms such as EndoTool, a leading software platform that offers capabilities for inpatient insulin dosing and […]
Diabetes
ViCentra launches smartphone-controlled Kaleido automated insulin patch pump system
ViCentra announced today that it launched its Kaleido smartphone-controlled hybrid closed-loop insulin delivery system in Europe. The new system combines the company’s Kaleido patch pump with Diabeloop’s DBLG2 algorithm and the Dexcom G7 continuous glucose monitor (CGM). It comes on the heels of Diabeloop’s CE mark for the next-generation algorithm paired with G7, announced yesterday. […]
CGM maker Sava names new chief commercial officer
Sava Technologies today announced the appointment of John Bernard as its new chief commercial officer (CCO). London-based Sava, which develops a minimally invasive molecular sensing platform for continuous glucose monitoring (CGM), says the appointment marks a “decisive step” in its transition from clinical and technical progress to commercial execution. The company designed its multi-molecule biosensor […]
Diabeloop gets CE mark for next-gen algorithm paired with Dexcom G7, ViCentra Kaleido
Diabeloop announced today that it received CE mark approval for its latest automated insulin delivery (AID) platform, DBLG2. CE mark approval comes not long after FDA approval in December 2025. The algorithm initially received CE mark last year but now has European approval for compatibility with next-generation devices. With clearance for DBLG2, integrated with the […]
Senseonics posts mixed Q1, raises 2026 guidance amid growing Eversense 365 sales
Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations. However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 […]
Tandem to submit tubeless pump to FDA with Street-beating Q1 on record pump shipments
Tandem Diabetes Care (Nasdaq:TNDM) today shared its plans to submit a tubeless insulin pump to the FDA. On the company’s first-quarter earnings call, President and CEO John Sheridan outlined the plans for Mobi Tubeless, the company’s existing Mobi pump that utilizes a novel infusion set option for tubeless insulin delivery. Currently, Insulet offers the leading […]
Glucotrack submits long-term implantable CBGM for FDA IDE
Glucotrack (Nasdaq:GCTK) announced today that it submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE. FDA IDE (investigational device exemption) would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of […]
Glucose monitor maker LifeScan names new CEO
Blood glucose monitoring company LifeScan announced today that it appointed Jonathan Salkin as its new CEO, effective immediately. Salkin succeeds Michael Hooks and James Rushing, who served as co-CEOs in an interim capacity. They took over on a temporary basis in January 2026, following the retirement of longtime CEO Valerie Asbury. Malvern, Pennsylvania-based LifeScan plans […]
Insulet sales grow 34% in Street-beating Q1 as company ups growth guidance
Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on Wall Street. Shares of PODD ticked up 5% to $175.79 before the market opened today. However, at midday, shares were down 8.2% at $153.78 apiece, potentially in response to scrutiny over U.S. trends and new patient starts. The […]
Embecta ‘disappointed’ with Q2 results that fell below expectations, cuts 2026 guidance
Embecta (Nasdaq:EMBC) today reported second-quarter financial results that fell shy of expectations on Wall Street. The BD Diabetes spinoff attributed shortcomings to increased competitive dynamics and softness in overall market volumes in the U.S. Its international business performed in line with expectations, however. Shares of EMBC fell 43% to $5.29 apiece before the market opened […]
